The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
 
 

Inhibition of non-small-cell lung cancer growth by combined fulvestrant and vandetanib.

Evaluation of: Siegfried JM, Gubish CT, Rothstein ME, Henry C, Stabile LP. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. J. Thorac. Oncol. 7(3), 485-495 (2012). Targeting the EGF receptor (EGFR) with tyrosine kinase inhibitors (TKIs) shows clinical efficacy for some non-small-cell lung cancer (NSCLC) patients. Recent studies have demonstrated that NSCLCs express estrogen receptors and that fulvestrant, an antiestrogen that reduces estrogen receptor protein, inhibits cell proliferation. Combination of a TKI targeting EGFR and fulvestrant shows greater efficacy than TKI or fulvestrant alone. This study demonstrated that treatment of NSCLC cells with vandetanib, a TKI of EGFR and VEGF receptor, and fulvestrant showed greater efficacy for inhibition of cell proliferation in vitro or xenograft tumor growth in vivo than either drug alone. These preclinical data provide rationale for a clinical trial to test efficacy in NSCLC patients.[1]

References

 
WikiGenes - Universities